Takeda Pharmaceutical Company’s Xilio Therapeutics XLO Stock Holding History

Takeda Pharmaceutical Company’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.24M	Hold	105,366	–	–	7.59%	3
2025 Q2	$1M	Hold	105,366	–	–	5.13%	3
2025 Q1	$1.07M	Hold	105,366	–	–	6.6%	3
2024 Q4	$1.42M	Hold	105,366	–	–	5.33%	3
2024 Q3	$1.16M	Hold	105,366	–	–	3.06%	6
2024 Q2	$1.4M	Hold	105,366	–	–	0.6%	8
2024 Q1	$1.59M	Hold	105,366	–	–	0.55%	9
2023 Q4	$811K	Buy	+105,366	New	+$2.08M	0.25%	11

Other funds holding XLO

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TOCUITCONY

Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

Takeda Pharmaceutical Company's XLO Position: Q3 2025 in Review

Takeda Pharmaceutical Company held its Xilio Therapeutics (XLO) position steady in Q3 2025 at 105,366 shares worth $1.24M. The position accounts for 7.59% of the portfolio, ranked #3.

Takeda Pharmaceutical Company first reported a position in XLO in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.59M in Q1 2024. 36 funds tracked by Wall St. Rank hold XLO as of Q3 2025.

Takeda Pharmaceutical Company held 105,366 shares of Xilio Therapeutics worth $1.24M as of Q3 2025.
Takeda Pharmaceutical Company left its Xilio Therapeutics share count unchanged in Q3 2025.
Xilio Therapeutics made up 7.59% of Takeda Pharmaceutical Company's portfolio in Q3 2025, its #3 holding.
Takeda Pharmaceutical Company first reported a position in Xilio Therapeutics in Q4 2023 and has held it in 8 quarters since.
Takeda Pharmaceutical Company's Xilio Therapeutics position peaked at $1.59M in Q1 2024.
36 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.